Characteristics of patients with and without clonal evolution
| . | Start of ruxolitinib . | P . | Discontinuation . | P . | ||
|---|---|---|---|---|---|---|
| No clonal evolution (N = 40) . | Clonal evolution (N = 22) . | No clonal evolution (N = 40) . | Clonal evolution (N = 22) . | |||
| Age, y | 65 (43-80) | 68 (51-84) | .310 | 70 (44-84) | 70 (53-87) | .517 |
| Female | 16 (40) | 8 (36) | 1.00 | |||
| Diagnosis | .461 | |||||
| PMF | 26 (65) | 16 (73) | ||||
| PPV | 8 (20) | 5 (23) | ||||
| PET | 6 (15) | 1 (4) | ||||
| Median Hgb, g/dL | 10.9 (7.4-16.9) | 10.3 (7.2-14.3) | .576 | 9.6 (5.7-15.4) | 8.8 (6.1-12.1) | .233 |
| Hgb < 10 g/dL | 14 (35) | 11 (50) | .288 | 21 (53) | 14 (64) | .435 |
| Median WBC (range), ×109/L | 18 (3-52) | 25 (3-159) | .119 | 16.4 (2.8-225) | 31 (3.5-142) | .328 |
| WBC > 25 × 109/L | 10 (25) | 10 (46) | .155 | 15 (38) | 12 (55) | .285 |
| Median Plt (range), ×109/L | 262 (103-969) | 220 (101-761) | .162 | 105 (11-922) | 74 (20-430) | .188 |
| Plt < 250 × 109/L | 18 (45) | 13 (59) | .426 | |||
| Plt < 100 × 109/L | 0 | 0 | 20(50) | 16 (73) | .109 | |
| Median PBBL (range), % | 0 (0-8) | 1.0 (0-4) | .084 | 2 (0-70) | 2 (0-21) | .619 |
| Median LDH (range), IU | 1704 (661-4309) | 1974 (783-5006) | .410 | 2075 (196-4200) | 1617 (660-9711) | .953 |
| Median Spln (range), cm | 20 (0-29) | 16 (0-30) | .782 | 13 (0-29) | 15 (0-24) | .400 |
| TSF Dep, n | 7 (18) | 10 (46) | .035 | 14 (36) | 11 (50) | .416 |
| Abn cytogenetics, n | 18 (45) | 6 (29) | .275 | 17/25 (68) | 6/9 (67) | 1.0 |
| Complex karyotype,* n | 7 (18) | 0/21 | .084 | 9/26 (35) | 1/10 (10) | .223 |
| JAK2+, n | 35 (88) | 18 (82) | .709 | |||
| Median JAK2 (range), % | 60 (0-99) | 54 (0-98) | .872 | 54 (0-99) | 57 (0-98) | .698 |
| Median TTD (range), mo | 31 (2-100) | 23 (2-64) | .414 | |||
| . | Start of ruxolitinib . | P . | Discontinuation . | P . | ||
|---|---|---|---|---|---|---|
| No clonal evolution (N = 40) . | Clonal evolution (N = 22) . | No clonal evolution (N = 40) . | Clonal evolution (N = 22) . | |||
| Age, y | 65 (43-80) | 68 (51-84) | .310 | 70 (44-84) | 70 (53-87) | .517 |
| Female | 16 (40) | 8 (36) | 1.00 | |||
| Diagnosis | .461 | |||||
| PMF | 26 (65) | 16 (73) | ||||
| PPV | 8 (20) | 5 (23) | ||||
| PET | 6 (15) | 1 (4) | ||||
| Median Hgb, g/dL | 10.9 (7.4-16.9) | 10.3 (7.2-14.3) | .576 | 9.6 (5.7-15.4) | 8.8 (6.1-12.1) | .233 |
| Hgb < 10 g/dL | 14 (35) | 11 (50) | .288 | 21 (53) | 14 (64) | .435 |
| Median WBC (range), ×109/L | 18 (3-52) | 25 (3-159) | .119 | 16.4 (2.8-225) | 31 (3.5-142) | .328 |
| WBC > 25 × 109/L | 10 (25) | 10 (46) | .155 | 15 (38) | 12 (55) | .285 |
| Median Plt (range), ×109/L | 262 (103-969) | 220 (101-761) | .162 | 105 (11-922) | 74 (20-430) | .188 |
| Plt < 250 × 109/L | 18 (45) | 13 (59) | .426 | |||
| Plt < 100 × 109/L | 0 | 0 | 20(50) | 16 (73) | .109 | |
| Median PBBL (range), % | 0 (0-8) | 1.0 (0-4) | .084 | 2 (0-70) | 2 (0-21) | .619 |
| Median LDH (range), IU | 1704 (661-4309) | 1974 (783-5006) | .410 | 2075 (196-4200) | 1617 (660-9711) | .953 |
| Median Spln (range), cm | 20 (0-29) | 16 (0-30) | .782 | 13 (0-29) | 15 (0-24) | .400 |
| TSF Dep, n | 7 (18) | 10 (46) | .035 | 14 (36) | 11 (50) | .416 |
| Abn cytogenetics, n | 18 (45) | 6 (29) | .275 | 17/25 (68) | 6/9 (67) | 1.0 |
| Complex karyotype,* n | 7 (18) | 0/21 | .084 | 9/26 (35) | 1/10 (10) | .223 |
| JAK2+, n | 35 (88) | 18 (82) | .709 | |||
| Median JAK2 (range), % | 60 (0-99) | 54 (0-98) | .872 | 54 (0-99) | 57 (0-98) | .698 |
| Median TTD (range), mo | 31 (2-100) | 23 (2-64) | .414 | |||
Abn, abnormal; BM, bone marrow; LDH, lactate dehydrogenase; PBBL, peripheral blood blasts; PET, post–essential thrombocythemia; Plt, platelets; PMF, primary myelofibrosis; PPV, post–polycythemia vera; Spln, spleen; TSF, transfusion; TTD, time to treatment discontinuation.
Complex karyotype is defined as 3 or more unrelated abnormalities.